BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis
Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir
Promising findings for therapeutic hepatitis C vaccine TG4040
Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity
![Josep Llovet, University of Barcelona [Photo by Liz Highleyman, hivandhepatitis.com]](https://ik.imagekit.io/ftwmbwg7i/tr:w-640,h-480,q-80,fo-auto,f-auto/https%3A%2F%2Fcdn.craft.cloud%2F019ecfe4-fa59-7378-875f-6ad629d65a81%2Fassets%2F2012-04%2Fbrivanib-did-not-improve-overall-liver-cancer-survival-but-did-show-anti-tumour-activity.jpg?ik-s=72da0bc390c58f9e219054c2b59b14a731faf359&ik-t=7552444800)
GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks
![Kris Kowdley, Virginia Mason Medical Center, Seattle [Photo by Liz Highleyman, hivandhepatitis.com]](https://ik.imagekit.io/ftwmbwg7i/tr:w-640,h-480,q-80,fo-auto,f-auto/https%3A%2F%2Fcdn.craft.cloud%2F019ecfe4-fa59-7378-875f-6ad629d65a81%2Fassets%2F2012-04%2Fgs-7977-with-interferon-ribavirin-cures-most-treatment-naive-hepatitis-c-patients-in-12-weeks.jpg?ik-s=162dce97971b5a079c73f39b4d72ea056f715705&ik-t=7552444800)
Incidence of hepatitis C re-infection and clearance may be understimated
Abbott interferon-free HCV combinations show early promise in untreated patients
Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy
Adding TMC435 boosts response for difficult-to-treat hepatitis C patients
Hepatitis C drug alisporivir is effective, but pancreatitis a concern
Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment
Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos
